An open study with reversible MAO-A inhibitors in complicated Parkinson's disease
Ruggieri, S.; Fabbrini, G.; Bramante, L.; DePandis, F.; Stocchi, F.; Barbanti, P.; Vacca, L.; Manfredi, M.
Advances in Neurology 69: 595-598
1996
ISSN/ISBN: 0091-3952 PMID: 8615185 Document Number: 462551
Document emailed within 1 workday
Related Documents
Rabasseda, X. 1999: Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies Drugs of Today 35(9): 701-717Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Olanow, C.W. 1993: MAO-B inhibitors in Parkinson's disease Advances in Neurology 60: 666-671
Agnoli, A.; Stocchi, F.; Carta, A.; Antonini, A.; Bragoni, M.; Ruggieri, S.A. 1988: Continuous dopaminergic stimulation in the management of complicated Parkinson's disease Mount Sinai Journal of Medicine new York 55(1): 62-66
Youdim, M.B. 1986: Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease Journal of Neural Transmission. Supplementum 22: 91-105
Litvinenko, I.V.; Odinak, M.M.; Mogil'naia, V.I.; Perstenev, S.V. 2008: Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(10): 37-42
Molina, J.A.; Jiménez-Jiménez, F.J.; Ortí-Pareja, M. 1999: Motor and mental complications in the long-term treatment of complicated Parkinson's disease with levodopa Revista de Neurologia 28(10): 982-990
Zhang, Z.-L.; Ji, X.-Q.; Zhao, S.-H.; Zhang, J.-J.; Kang, T.; Yang, X.-J. 2008: Randomized controlled study on effects of the needling method for regulating spleen-stomach on coronary heart disease complicated by type 2 diabetes mellitus complicated Zhongguo Zhen Jiu 28(9): 629-633
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Joffe, R.T.; Schuller, D.R. 1993: An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression Journal of Clinical Psychiatry 54(7): 269-271
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Phillips, K.A. 1996: An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder Psychopharmacology Bulletin 32(1): 175-180
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Sale, P.; De Pandis, M.F.; Vimercati, S.L.; Sova, I.; Foti, C.; Tenore, N.; Fini, M.; Stocchi, F.; Albertini, G.; Franceschini, M.; Galli, M. 2013: The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects European Journal of Physical and Rehabilitation Medicine 49(2): 161-167
Pokala, N.; Sadhasivam, S.; Kiran, R.P.; Parithivel, V. 2007: Complicated appendicitis--is the laparoscopic approach appropriate? a comparative study with the open approach: outcome in a community hospital setting American Surgeon 73(8): 737
Marangell, L.B.; Johnson, C.R.; Kertz, B.; Zboyan, H.A.; Martinez, J.M. 2002: Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study Journal of Clinical Psychiatry 63(5): 391-395
Enzi, G. 1997: A multicenter open study of dexfenfluramine in Italy. the efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. the DIMOS Group Terapevticheskii Arkhiv 69(5): 71-75
Koliada, A.K.; Vaĭserman, A.M.; Krasnenkov, D.S.; Karaban', I.N. 2014: The study of telomere length in patients with Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 114(8): 58-61
Van Laar, T.; Boon, A.J.W.; Bloem, B.R. 2010: Rasagiline is not for all Parkinson disease patients: the ADAGIO study Nederlands Tijdschrift Voor Geneeskunde 154: A2496
Baltasar-Rodríguez, L.M.; Millán-Guerrero, R.O.; Aceves-Themsel, R.; Isais-Millán, S.; Delgado-Enciso, I.án. 2006: Longitudinal study of three families with familial Parkinson's disease Gaceta Medica de Mexico 142(5): 387-391